Skip to content
Resources > Reports

How IR Professionals Can Be a Strategic Partner to C-Suite During Economic Uncertainty

In highly volatile economic times, it's paramount for a management team to communicate precise and timely messaging aligned with their respective strategic narratives.

With concerns about inflation, supply chain irregularities due to the conflict in Eastern Europe, and the lingering impacts of COVID-19, messaging can be incredibly impactful and challenging. That’s where investor relations (IR) professionals come in.

Today, investor relations serve as the voice of the company. Every company aims to consistently develop investor confidence and effectively communicate performance, updates, forecasts, and overall strategy with shareholders, internal stakeholders, and the broader investment community. The bottom line: the role of IR professionals in all these efforts is underscored even more in these difficult times.

In this whitepaper, you will learn:

  • The role IR professionals play as strategic partners to the C-suite, contextualized in today's economic climate
  • How you can be an instrumental resource and partner for management
  • AI capabilities and the value it can add to your C-suite's confidence and company vision

Explore more

Enterprise Software: Assessing AI Adoption Trends

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
Title slide: Enterprise Software: Assessing AI Adoption Trends, by Michelle Brophy and Sean Carmichael, featuring a computer illustration and AI logo.

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.